Clinical Trial Update: Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults [Phase 2]

View source ↗

Summary

Phase 2 trial update for QBKPN Site-Specific Immunomodulator to improve innate immune function and reduce respiratory tract infections in older adults; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• QBKPN Site-Specific Immunomodulator (QBKPN)

Snippet

Sponsor: Qu Biologics Inc. | Conditions: Immune Deficiency | Phase 2 | Status: RECRUITING